Welcome to our dedicated page for Ocular Therapeut SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ocular Therapeutix, Inc. (NASDAQ: OCUL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including 8-K current reports and other documents filed with the U.S. Securities and Exchange Commission. These filings give detailed insight into Ocular Therapeutix’s clinical programs, financing activities, and key corporate events as it advances ophthalmic therapies based on its ELUTYX bioresorbable hydrogel technology.
Recent 8-K filings describe the structure and status of the AXPAXLI (OTX-TKI) registrational trials in wet age-related macular degeneration (wet AMD), including the SOL-1 and SOL-R Phase 3 studies, as well as plans for the SOL-X long-term extension trial. They also outline the design of the HELIOS-2 and HELIOS-3 Phase 3 trials in non-proliferative diabetic retinopathy (NPDR), the use of a novel ordinal diabetic retinopathy severity score (DRSS) endpoint, and Special Protocol Assessment (SPA) agreements with the FDA.
Other filings cover capital markets transactions, such as the September 30, 2025 underwriting agreement for a large common stock offering, expected net proceeds, and the company’s view of its cash runway into future years. Additional 8-Ks furnish quarterly financial results press releases, describe inducement equity awards under Nasdaq Listing Rule 5635(c)(4), and discuss notices of allowance from the U.S. Patent and Trademark Office related to AXPAXLI methods of use.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and can be paired with AI-powered summaries that explain the key points of lengthy documents like 8-Ks or registration statements in plain language. Users can quickly see how Ocular Therapeutix reports on trial designs, primary endpoints, regulatory interactions, cash resources, and potential patent protection. For investors tracking OCUL, this page is a central place to review official disclosures about clinical progress, financing arrangements, and other material events that may influence the company’s ophthalmology-focused pipeline and commercial product DEXTENZA.
Ocular Therapeutix insider grant summary: Nadia Waheed, the companys Chief Medical Officer, received equity awards on 08/12/2025. She was granted 40,363 restricted stock units (RSUs), each representing a right to one share, which vest over three years in equal annual installments beginning February 11, 2026. She also received a stock option to purchase 122,923 shares at an exercise price of $12.48 per share; the option vests partially (7/48) on September 11, 2025, with the remainder vesting monthly through February 11, 2029, and expires August 11, 2035. Following these transactions, Waheed reports beneficial ownership of 247,168 shares and 122,923 underlying option shares.
Pravin Dugel, Executive Chairman, President and CEO of Ocular Therapeutix (OCUL), reported a series of gift transfers of common stock among family-related parties and an irrevocable trust. On April 28, 2025 he transferred 200,332 shares to his spouse for no consideration and on June 12, 2025 he transferred 50,029 shares to his spouse for no consideration. On August 11, 2025 the spouse transferred 250,361 shares to the "Pravin Dugel 2024 Irrevocable Trust" for no consideration.
The filing states Mr. Dugel is the trustee and sole beneficiary of the Trust during his lifetime and "remains the beneficial owner of the securities held by the Trust." Reported direct beneficial ownership after the June transfer is 3,248,738 shares, and the Trust holds 250,361 shares indirectly.
On 06/11/2025, Ocular Therapeutix (OCUL) Chief Commercial Officer Steve Lawrence Meyers filed a Form 3, establishing his initial beneficial ownership. He directly owns 152,728 common shares, including 117,317 unvested RSUs granted in 2023-2025 under the company’s 2021 Stock Incentive Plan. In addition, Meyers holds four option grants totaling 512,000 shares with strike prices ranging from $3.88 to $7.44 and expirations between 2032-2035; each option vests monthly over four years. The filing is routine, reflects no open-market purchases or sales, and does not alter the company’s capital structure.
Ocular Therapeutix (OCUL) filed a Form 3 disclosing the initial beneficial ownership of its newly appointed Chief Business Officer, Namrata Saroj. The filing reports direct ownership of 200,000 unvested restricted stock units (RSUs) that will vest in three equal annual installments beginning on the first anniversary of her start date.
Derivative holdings include 466,000 stock options spread across three grants: 50,000 options already fully vested at an exercise price of $9.95 expiring 02/27/2034; 100,000 options granted 02/28/2024 at $9.95 vesting 1/48 monthly after an initial one-year cliff; and 316,000 options granted 11/04/2024 at $10.27 with similar four-year vesting. All holdings are reported as direct ownership.
The filing is routine, conveys no operational or financial performance data, and does not imply the insider owns more than 10 % of outstanding shares.